{
    "id": 3568,
    "fullName": "NRAS Q61H",
    "impact": "missense",
    "proteinEffect": "loss of function",
    "geneVariantDescriptions": [
        {
            "description": "NRAS Q61H is a hotspot mutation that lies within a GTP-binding region of the Nras protein (UniProt.org). Q61H confers a loss of function to Nras protein as indicated by increased GTP-bound Nras, which leads to increased downstream pathway activation and cell proliferation in cell culture (PMID: 23103856).",
            "references": [
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 2103,
                    "pubMedId": 23103856,
                    "title": "Oncogenic and wild-type Ras play divergent roles in the regulation of mitogen-activated protein kinase signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23103856"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 4893,
        "geneSymbol": "NRAS",
        "terms": [
            "NRAS",
            "ALPS4",
            "CMNS",
            "N-ras",
            "NCMS",
            "NRAS1",
            "NS6"
        ]
    },
    "variant": "Q61H",
    "createDate": "03/05/2015",
    "updateDate": "09/20/2018",
    "referenceTranscriptCoordinates": {
        "id": 162458,
        "transcript": "NM_002524",
        "gDna": "chr1:g.114713907T>A",
        "cDna": "c.183A>T",
        "protein": "p.Q61H",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 14132,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination therapy of Alpelisib (BYL719) and Binimetinib (MEK162) led to a synergistic effect in rhabdomyosarcoma cells harboring NRAS Q61H, demonstrating cell death in culture (PMID: 29437705).",
            "molecularProfile": {
                "id": 3374,
                "profileName": "NRAS Q61H"
            },
            "therapy": {
                "id": 1311,
                "therapyName": "Alpelisib + Binimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 3247,
                "name": "rhabdomyosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11474,
                    "pubMedId": 29437705,
                    "title": "NRAS-Mutated Rhabdomyosarcoma Cells Are Vulnerable to Mitochondrial Apoptosis Induced by Coinhibition of MEK and PI3K\u03b1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29437705"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18688,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ARS1620 treatment resulted in minor reduction of Erk phosphorylation and had no effect on apoptosis in lung carcinoma cells harboring KRAS G12C and NRAS Q61H in culture (PMID: 31534020).",
            "molecularProfile": {
                "id": 33499,
                "profileName": "KRAS G12C NRAS Q61H"
            },
            "therapy": {
                "id": 7862,
                "therapyName": "ARS1620",
                "synonyms": null
            },
            "indication": {
                "id": 3905,
                "name": "lung carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 16366,
                    "pubMedId": 31534020,
                    "title": "Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31534020"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18691,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Afinitor (everolimus), Linsitinib (OSI-906), and Mekinist (trametinib) triple combination treatment inhibited Erk and S6 phosphorylation, resulted in apoptosis in lung carcinoma cells harboring KRAS G12C and NRAS Q61H in culture (PMID: 31534020).",
            "molecularProfile": {
                "id": 33499,
                "profileName": "KRAS G12C NRAS Q61H"
            },
            "therapy": {
                "id": 8786,
                "therapyName": "Everolimus + Linsitinib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 3905,
                "name": "lung carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16366,
                    "pubMedId": 31534020,
                    "title": "Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31534020"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18690,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) treatment induced apoptosis in lung carcinoma cells harboring KRAS G12C and NRAS Q61H in culture (PMID: 31534020).",
            "molecularProfile": {
                "id": 33499,
                "profileName": "KRAS G12C NRAS Q61H"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 3905,
                "name": "lung carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16366,
                    "pubMedId": 31534020,
                    "title": "Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31534020"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18689,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ARS1620, Afinitor (everolimus), and Linsitinib (OSI-906) triple combination treatment inhibited Erk and S6 phosphorylation but had no effect on apoptosis in lung carcinoma cells harboring KRAS G12C and NRAS Q61H in culture (PMID: 31534020).",
            "molecularProfile": {
                "id": 33499,
                "profileName": "KRAS G12C NRAS Q61H"
            },
            "therapy": {
                "id": 8792,
                "therapyName": "ARS1620 + Everolimus + Linsitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3905,
                "name": "lung carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 16366,
                    "pubMedId": 31534020,
                    "title": "Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31534020"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 3374,
            "profileName": "NRAS Q61H",
            "profileTreatmentApproaches": [
                {
                    "id": 16496,
                    "name": "MEK1 Inhibitor",
                    "profileName": "NRAS Q61H"
                },
                {
                    "id": 16493,
                    "name": "PIK3CA inhibitor",
                    "profileName": "NRAS Q61H"
                },
                {
                    "id": 16495,
                    "name": "RAS Inhibitor (Pan)",
                    "profileName": "NRAS Q61H"
                },
                {
                    "id": 16497,
                    "name": "MEK inhibitor (Pan)",
                    "profileName": "NRAS Q61H"
                },
                {
                    "id": 16494,
                    "name": "PI3K Inhibitor (Pan)",
                    "profileName": "NRAS Q61H"
                },
                {
                    "id": 16498,
                    "name": "MEK2 Inhibitor",
                    "profileName": "NRAS Q61H"
                }
            ]
        },
        {
            "id": 33499,
            "profileName": "KRAS G12C NRAS Q61H",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 162458,
            "transcript": "NM_002524",
            "gDna": "chr1:g.114713907T>A",
            "cDna": "c.183A>T",
            "protein": "p.Q61H",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}